CN102085360B - 原料含有水蛭素的药物组合物及其用途 - Google Patents
原料含有水蛭素的药物组合物及其用途 Download PDFInfo
- Publication number
- CN102085360B CN102085360B CN201110007683XA CN201110007683A CN102085360B CN 102085360 B CN102085360 B CN 102085360B CN 201110007683X A CN201110007683X A CN 201110007683XA CN 201110007683 A CN201110007683 A CN 201110007683A CN 102085360 B CN102085360 B CN 102085360B
- Authority
- CN
- China
- Prior art keywords
- hirudin
- hyaluronidase
- medicine
- fibrinolytic
- plain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000007625 Hirudins Human genes 0.000 title claims abstract description 57
- 108010007267 Hirudins Proteins 0.000 title claims abstract description 57
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 title claims abstract description 57
- 229940006607 hirudin Drugs 0.000 title claims abstract description 57
- 239000002994 raw material Substances 0.000 title claims abstract description 38
- 239000000203 mixture Substances 0.000 title abstract description 4
- 239000003814 drug Substances 0.000 claims abstract description 77
- 108010003272 Hyaluronate lyase Proteins 0.000 claims abstract description 51
- 102000001974 Hyaluronidases Human genes 0.000 claims abstract description 51
- 229960002773 hyaluronidase Drugs 0.000 claims abstract description 51
- 208000026106 cerebrovascular disease Diseases 0.000 claims abstract description 44
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 7
- 230000006378 damage Effects 0.000 claims abstract description 7
- 208000014674 injury Diseases 0.000 claims abstract description 6
- 230000003511 endothelial effect Effects 0.000 claims abstract description 4
- 239000003527 fibrinolytic agent Substances 0.000 claims description 48
- 230000003480 fibrinolytic effect Effects 0.000 claims description 48
- 238000002360 preparation method Methods 0.000 claims description 27
- 239000002775 capsule Substances 0.000 claims description 17
- 230000002792 vascular Effects 0.000 claims description 3
- 238000012360 testing method Methods 0.000 abstract description 38
- 206010008118 cerebral infarction Diseases 0.000 abstract description 16
- 201000006474 Brain Ischemia Diseases 0.000 abstract description 12
- 241000699670 Mus sp. Species 0.000 abstract description 8
- 241000700159 Rattus Species 0.000 abstract description 7
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract description 6
- 230000000144 pharmacologic effect Effects 0.000 abstract description 4
- 229940126678 chinese medicines Drugs 0.000 abstract description 2
- 101710084517 Hementerin Proteins 0.000 abstract 2
- 208000019553 vascular disease Diseases 0.000 abstract 2
- 229940079593 drug Drugs 0.000 description 24
- 230000034994 death Effects 0.000 description 12
- 231100000517 death Toxicity 0.000 description 12
- 210000004556 brain Anatomy 0.000 description 10
- 210000002889 endothelial cell Anatomy 0.000 description 9
- 208000024172 Cardiovascular disease Diseases 0.000 description 7
- 206010008190 Cerebrovascular accident Diseases 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 208000006011 Stroke Diseases 0.000 description 7
- 230000005779 cell damage Effects 0.000 description 7
- 208000037887 cell injury Diseases 0.000 description 7
- 230000002526 effect on cardiovascular system Effects 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 230000008859 change Effects 0.000 description 6
- 210000000269 carotid artery external Anatomy 0.000 description 5
- 208000029078 coronary artery disease Diseases 0.000 description 5
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000002146 bilateral effect Effects 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical group C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000004004 carotid artery internal Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 206010060860 Neurological symptom Diseases 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 238000011496 digital image analysis Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000005021 gait Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000003606 umbilical vein Anatomy 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 206010015995 Eyelid ptosis Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000003483 hypokinetic effect Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000003657 middle cerebral artery Anatomy 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
组别 | 面积 |
对照组 | 0.537±0.033** |
Ang II组 | 0.371±0.018 |
Ang II+试验1组 | 0.514±0.049** |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110007683XA CN102085360B (zh) | 2011-01-14 | 2011-01-14 | 原料含有水蛭素的药物组合物及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110007683XA CN102085360B (zh) | 2011-01-14 | 2011-01-14 | 原料含有水蛭素的药物组合物及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102085360A CN102085360A (zh) | 2011-06-08 |
CN102085360B true CN102085360B (zh) | 2012-07-25 |
Family
ID=44097521
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110007683XA Active CN102085360B (zh) | 2011-01-14 | 2011-01-14 | 原料含有水蛭素的药物组合物及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102085360B (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1911250A (zh) * | 2006-08-21 | 2007-02-14 | 北京润德康医药技术有限公司 | 一种以水蛭提取物为活性成分的中药肠溶口服制剂及其制备方法 |
-
2011
- 2011-01-14 CN CN201110007683XA patent/CN102085360B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1911250A (zh) * | 2006-08-21 | 2007-02-14 | 北京润德康医药技术有限公司 | 一种以水蛭提取物为活性成分的中药肠溶口服制剂及其制备方法 |
Non-Patent Citations (12)
Title |
---|
代全国,尹明浩.《水蛭素治疗脑血管疾病研究进展》.《延边大学医学学报》.2007,第30卷(第3期),第215-217页. * |
侯倩等.《水蛭治疗脑梗塞相关研究近况》.《实用医药杂志》.2004,第21卷(第12期),第1134-1135页. * |
刘君.《蚂蝗抗凝血的活性成分研究》.《辽宁中医学院药学专业博士学位论文》.2005,第7-8页. * |
刘贞丽,潘继富,董传海.《水蛭的药理作用及其临床应用》.《时珍国医国药》.2002,第13卷(第6期),第376-377页. * |
康凤珍.《小议水蛭在心脑血管疾病方面的应用》.《甘肃省中医药学会2008年学术年会论文集》.2008,第107-109页. * |
张桂霞.《水蛭素治疗脑血管疾病研究探析》.《实用中医内科杂志》.2008,第22卷(第8期),第50-51页. * |
李梅 等.《中药水蛭对血液流变学影响的临床研究》.《内蒙古中医药》.2008,(第1期),第9-10页. * |
欧兴长.《水蛭活血有效成分研究概况》.《中国中医基础医学杂志》.1997,第4卷(第2期),第60-63页. * |
潘贺,刚宏林,苏云明.《中药水蛭的活性成分及药理作用研究概况》.《中医药信息》.2006,第23卷(第1期),第20-21页. * |
程新法等.《水蛭的综合研究近况》.《中医文献杂志》.1997,(第3期),第44-45页. * |
陈东明等.《纤溶酶治疗急性脑梗塞的临床观察》.《心血管康复医学杂志》.2005,第14卷(第1期),第51-52页. * |
陈淑莹等.《水蛭的药效学及临床研究进展》.《浙江实用医学》.1997,第2卷(第4期), * |
Also Published As
Publication number | Publication date |
---|---|
CN102085360A (zh) | 2011-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Dox et al. | Melloni's illustrated medical dictionary | |
ES2435080T3 (es) | Procedimiento de expansión de células madre adultas de sangre, en particular sangre periférica, y aplicación relativa en el campo médico | |
Airaodion et al. | Carica papaya leaves might cause miscarriage | |
Allen | Local and Regional Anesthesia: With Chapters on Spinal, Epidural, Paravertebral, and Parasacral Analgesia, and Other Applications of Local and Regional Anesthesia to the Surgery of the Eye, Ear, Nose and Throat, and to Dental Practice | |
CN100515431C (zh) | 海参活性物质作为药物或保健品的应用 | |
CN107880109B (zh) | 一种***来源肽及其制备方法和用途 | |
CN102085360B (zh) | 原料含有水蛭素的药物组合物及其用途 | |
CN102138967A (zh) | 香青兰总黄酮在制备防治脑血管疾病药物中的应用 | |
GB2568928A (en) | Neuroprotective composition, preparation process thereof and medical uses thereof | |
CN104586866A (zh) | 一种治疗脑血管疾病的药物组合物 | |
CN102813914A (zh) | 一种用于治疗或预防脑血管及相关疾病的药物组合物 | |
CN105343565A (zh) | 一种治疗深部真菌感染的中药 | |
US20190167727A1 (en) | Neuroprotective composition, preparation process thereof and medical uses thereof | |
CN101744955A (zh) | 一种用于治疗缺血性脑血管病的药物 | |
CN104490872A (zh) | 2-(2-苯并呋喃基)-2-咪唑啉治疗神经***线粒体损伤疾病中的用途 | |
TWI310686B (zh) | ||
CN104069062B (zh) | 一种防治缺血性心脑血管疾病的豆腐果苷注射剂及其制备方法与应用 | |
Gould | The Student's Medical Dictionary: Including All the Words and Phrases Generally Used in Medicine, with Their Proper Pronunciation and Definitions-- | |
CN102085359B (zh) | 原料含有水蛭素、纤溶素的药物组合物及其用途 | |
CN106727495B (zh) | 一类二氢黄酮化合物在制备心肌保护药物中的应用 | |
Gould | The student's medical dictionary | |
Qiu et al. | Combination treatment of motion sickness with scopolamine-loaded soluble microneedle patch and conventional training | |
Alsultan | The Effect of Aqueous Extract of Poppy Anemone Seeds on Embryonic Development in Mouse Model | |
Keating et al. | A New Pronouncing Dictionary of Medicine: Being a Voluminous and Exhaustive Hand-book of Medical and Scientific Terminology | |
CN105287620A (zh) | 长春西汀药物组合物及其在改善脑功能不全方面的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: Cao Jia Dian 400802 Chongqing city Wansheng District East Qingxi Bridge Applicant after: CHONGQING DUOPUTAI PHARMACEUTICAL Co.,Ltd. Address before: Cao Jia Dian 400802 Chongqing city Wansheng District East Qingxi Bridge Applicant before: CHONGQING SHIZHENGE PUSHENG PHARMACEUTICAL Co.,Ltd. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: CHONGQING SHIZHEN'GE PUSHENG PHARMACEUTICAL CO., LTD. TO: CHONGQING DUOPUTAI PHARMACEUTICAL CO., LTD. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: Cao Jia Dian 400802 Chongqing city Wansheng District East Qingxi Bridge Patentee after: CHONGQING DUOPUTAI PHARMACEUTICAL Co.,Ltd. Address before: Cao Jia Dian 400802 Chongqing city Wansheng District East Qingxi Bridge Patentee before: Chongqing Duoputai Pharmaceutical Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20240112 Address after: No. 303-7, Qingxi Bridge, Donglin Street, Wansheng Economic Development Zone, Qijiang District, Chongqing, 400800 Patentee after: Chongqing Duoputai Pharmaceutical Technology Co.,Ltd. Address before: 400802 Donglin Qingxi bridge in Wansheng District, Chongqing Patentee before: CHONGQING DUOPUTAI PHARMACEUTICAL Co.,Ltd. |
|
TR01 | Transfer of patent right |